TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2181915
Drug: Erythromycin-sulfisoxazole (Pediazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin-sulfisoxazole (Pediazole, 50 mg/kg/day in 3 divided doses)
Study: 534604
Drug: Oral candidiasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral candidiasis
Study: 27762489
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg thrice daily oral tranexamic acid plus HQ 4% cream nightly
Study: 27762489
Drug: HQ 4%
Normalized name: Hydroquinone 4%
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HQ 4% cream only
Study: 19965324
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide (Group 2, n=50, 10mg/ml)
Study: 15347371
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP, 100 microg Diskus, twice daily)
Study: 15347371
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (MON 10 mg, nocte)
Study: 11573668
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection of 3 ml of 0.5% plain bupivacaine by infusion pump over 3 min (1 ml min(‐1))
Study: 11573668
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection of 3 ml of 0.5% plain bupivacaine by hand over 10 s (18 ml min(‐1))
Study: 11573668
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection group
Study: 11573668
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection group
Study: 11041533
Drug: Zolpidem (ZPD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (ZPD, 10 mg)
Study: 2201724
Drug: Triazolam (TRZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (TRZ, 0.25 mg)
Study: 1862903
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine injections on demand
Study: 6127968
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg
Study: 6137171
Drug: Naloxone 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.015 mg/kg
Study: 26344009
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed.
Study: 26344009
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed (nonobese women).
Study: 24887209
Drug: ReNu MPS
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ReNu MPS (solution 1)
Study: 24887209
Drug: AQuify MPS
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AQuify MPS (solution 2)
Study: 19773417
Drug: High-dose daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose daclizumab (first dose: 2 mg/kg) with low-dose cyclosporine (CsA), mycophenolate mofetil (MMF), and steroids
Study: 19773417
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (CsA, MMF, steroids)
Study: 19773417
Drug: High-dose daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-dose daclizumab
Study: 16151461
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 mug daily for 5 weeks)
Study: 12162937
Drug: Alpha-tocopherol (AT)
Normalized name: alpha tocopherol
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-tocopherol (AT) therapy
Study: 10402091
Drug: Modafinil treatment
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil treatment for 9 weeks
Study: 2147537
Drug: Amlodipine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (0.4 to 45 micrograms/min/100 ml forearm tissue)
Study: 2147537
Drug: Amlodipine (44.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (44.5 micrograms/min/100 ml) + Verapamil (40 micrograms/min/100 ml)
Study: 29339650
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OIT) with a daily maintenance dose of 795 mg of peanut protein
Study: 25823600
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OIT)
Study: 20369614
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with indapamide and verapamil retard
Study: 20369614
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with indapamide and amlodipine
Study: 10219575
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg i.v. bolus at time of anesthesia)
Study: 10219575
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g at induction of anesthesia and 1 g every 6 h postoperatively, i.v. bolus)
Study: 27754731
Drug: Tele‐intervention Model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele‐intervention Model and Monitoring of Families of Drug Users (TMMFDU)
Study: 23768273
Drug: Home physical
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home physical therapy (HPT)
Study: 23768273
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy in conjunction with home physical therapy (MT-HPT)
Study: 20393694
Drug: Intra-operative periarticular
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative periarticular injection with local anaesthetic and adrenaline plus triamcinolone acetonide
Study: 20393694
Drug: Intra-operative periarticular
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative periarticular injection with local anaesthetic and adrenaline
Study: 10589859
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration (1000 U, 500 U, and 500 U before exercise)
Study: 6805451
Drug: Massive-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massive-dose vitamin A therapy
Study: 6805451
Drug: Repeated massive
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated massive vitamin A therapy
Study: 28950849
Drug: Bacteriophage (Pyo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriophage (Pyo bacteriophage) solution for 7 days
Study: 28950849
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for 7 days
Study: 28950849
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment according to sensitivity pattern for 7 days
Study: 21590473
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 0.2 mg
Study: 18356448
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg I/kg of body weight
Study: 18356448
Drug: 525 mg
Normalized name: psyllium 525 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 525 mg I/kg of body weight
Study: 18356448
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg I/kg of body weight
Study: 14700556
Drug: Pegvisomant (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (median dose 15 mg/day, range 10-40 mg)
Study: 14700556
Drug: GH receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH receptor blockade (not specified)
Study: 9413377
Drug: Conventional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulation treatment (medical group)
Study: 8435902
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose FSH (37.5 units daily, increased in 37.5 unit increments)
Study: 8435902
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose FSH (75 units daily, increased in 75 unit increments)
Study: 3630923
Drug: Nadolol (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (0.01, 0.02, and 0.04 mg/kg, maximum total dosage 10 mg)
Study: 29264967
Drug: Probiotic tablets
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablets containing Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307
Study: 31501124
Drug: Probiotic tablets
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablets
Study: 20551849
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplementation (1,000 mg of elemental calcium daily plus 400 IU of vitamin D3 daily)
Study: 16894619
Drug: Paroxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (40 mg/day)
Study: 16188206
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (4.5 g.d(‐1))
Study: 12651679
Drug: Ropivacaine 0.15%
Normalized name: ROPivacaine 0.15%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.15% plus 0.5 microg/mL of sufentanil
Study: 12651679
Drug: Ropivacaine 0.10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.10% plus 0.5 microg/mL of sufentanil
Study: 10765964
Drug: Chlorhexidine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (n = 30); varnish treatments at 6, 12, and 18 months after delivery.
Study: 10765964
Drug: Fluoride (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride (n = 33); varnish treatments at 6, 12, and 18 months after delivery.
Study: 1578942
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with additional allogeneic bone marrow transplantation
Study: 1578942
Drug: Stopping therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping therapy
Study: 3948357
Drug: Propranolol 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 180 or 240 mg daily
Study: 31892636
Drug: IV thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thrombolysis (alteplase 0.9 mg/kg)
Study: 27881914
Drug: Cocoa intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa intake once daily (17 g, except Sundays) for 12 weeks
Study: 27881914
Drug: Cocoa intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa intake twice daily every other day (17 g) for 12 weeks
Study: 21496065
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg co-administered with fesoterodine 8 mg
Study: 22727611
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg alone
Study: 17196454
Drug: Ranolazine (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (extended-release formulation in MARISA, CARISA, ERICA; immediate release in RAN080)
Study: 15071489
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine monotherapy
Study: 2687956
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment with radiotherapy and chemotherapy
Study: 3354256
Drug: Purified inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 7, and 21 (Group IA)
Study: 3354256
Drug: Purified inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 28, and 56 (Group IB)
Study: 3354256
Drug: Purified inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 3, 7, 14, 28, and 90 (Group II)
Study: 3354256
Drug: Purified inactivated
Normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, single booster for previously immunized individuals (Group III)
Study: 31221722
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BoNT) treatment
Study: 31221722
Drug: Open-label phase
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label phase with BoNT treatment
Study: 18560537
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (0.5 mg)
Study: 18560537
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (2 mg)
Study: 18560537
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (0.5 mg and 2 mg)
Study: 15953905
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 500/125 mg 3 times a day for 4 days
Study: 9801110
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.05% PGE1 in liposomal formulations
Study: 683118
Drug: Fe++ sulfate
Normalized name: ferrous sulfate Extended Release Oral Tablet [Slow-Fe]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe++ sulfate in a weak gelatine capsule (A)
Study: 683118
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (commercial preparation)
Study: 683118
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C (commercial preparation)
Study: 30380357
Drug: Fiber-multivitamin combination
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-multivitamin combination product (treatment group, n=20)
Study: 27464321
Drug: Swedish massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish massage therapy (SMT)
Study: 27097823
Drug: Doublebase™ gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase™ gel (2 fingertip units, twice daily for 4 weeks)
Study: 27097823
Drug: Diprobase® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprobase® cream (2 fingertip units, twice daily for 4 weeks)
Study: 20805984
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g dried broccoli sprouts for 4 weeks
Study: 12212215
Drug: Puerarin 400
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin 400 mg.d-1 for 10 days
Study: 12212215
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (inotropic agents, diuretic, vasodilator)
Study: 1868860
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (10 units of standard insulin)
Study: 3935405
Drug: Insulin-placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-placebo treatment
Study: 24924851
Drug: Intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent theta burst stimulation (iTBS) as add-on to cognitive-behavioral therapy (CBT)
Study: 15886753
Drug: SST-A octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST-A octreotide with adjuvant treatment (Group B)
Study: 12585097
Drug: Cordyceps powder
Normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordyceps powder 2‐4 g/d before meal and artemisinin 0.6 g/d after meal for 3 years
Study: 12585097
Drug: Tripterygiitotorum and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygiitotorum and/or Baoshenkang tablet
Study: 9583842
Drug: B‐group vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐group vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin)
Study: 9583842
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins alone (150 mg ascorbic acid, 67 mg RRR‐alpha‐tocopherol, and 9 mg beta‐carotene)
Study: 8562173
Drug: FA 200
Normalized name: INPEFA 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA 200 mg/m2 i.v. plus 5‐FU 400 mg/m2 i.v. on days 1‐5 every 3 weeks
Study: 8562173
Drug: 5‐FU 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 400 mg/m2 i.v. on days 1‐5 every 4 weeks
Study: 2766421
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine and Western Medicine (TCM-WM)
Study: 14714362
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (Control)
Study: 656890
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefuroxime intramuscularly and 1 g probenecid orally
Study: 656890
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime intramuscularly with 1 g probenecid orally
Study: 31400480
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) with Hormone Therapy (HT)
Study: 21348577
Drug: Visuomotor-imagery therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visuomotor-imagery therapy
Study: 21348577
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplementary therapy)
Study: 7862833
Drug: Drink containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink containing 50 g glucose
Study: 30529883
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d of high-cocoa chocolate for 4 weeks
Study: 29908991
Drug: MAGE-A3 immunotherapeutic
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapeutic (300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B, administered via intramuscular injections, up to 13 doses over 27 months)
Study: 29908991
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered via intramuscular injections, up to 13 doses over 27 months)
Study: 25397819
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, n=21)
Study: 11004260
Drug: Immune recovery
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune recovery uveitis patients undergoing highly active antiretroviral therapy
Study: 1627418
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 1 year
Study: 3676232
Drug: Low-energy diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy diet with egg supplementation (two whole eggs and two egg yolks daily)
Study: 23930204
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) in combination with capecitabine (C) and mitomycin C (M)
Study: 16557041
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (AA)
Study: 16557041
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (AA) + mood stabilizers
Study: 2526933
Drug: Carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (100 mg x 2)
Study: 2526933
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (1000 mg, 11 h prior to study)
Study: 27116023
Drug: Opioid dosing
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid dosing (morphine and oxycodone)
Study: 24618401
Drug: Weekly application
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly application of dehydrated human amnion/chorion membrane allograft
Study: 21095282
Drug: Highest uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest uric acid quartile (>10.4 mg/dL)
Study: 14705265
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy over five years
Study: 14705265
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy with permanent reduction in breast cancer incidence
Study: 14705265
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy with further treatment effects preventing new breast cancers for up to 10 years
Study: 14705265
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy with delayed breast cancer incidence
Study: 2203218
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol and 2% or 4% pilocarpine combination eye drops